MarketPeel
Insider Trading Intelligence
SB

Susan Bobulsky

ADPT
CHIEF COMMERCIAL OFFICER, MRD · ADAPTIVE BIOTECHNOLOGIES CORP · CIK 0001820885
FILING MIX · LIFETIME50%/50%
BUYS
12
SELLS
12
TOTAL VALUE
$3.12M
COMPANIES
1
ACTIVE SINCE
Aug 2020
HOLDINGS NOW
406,775
AVG SELL PX
$22.30
TRADE KIND
SHOWING 24 / 24
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
6 backtested trades · 8 horizons · 4 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Susan Bobulsky, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d6+66.67%-2.67%-0.05%-2.62%-2.68%
14d6+66.67%-1.58%+0.80%-2.37%-0.36%
30d6+66.67%-9.26%-1.00%-8.26%-2.89%
60d6+66.67%-1.95%+4.14%-6.09%-12.84%
90d6+50.00%+2.72%+6.63%-3.91%-4.34%
180d6(1 pending)+40.00%+10.02%+13.96%-3.95%+12.49%
1y6(1 pending)+40.00%+47.83%+22.56%+25.27%+81.18%
2y6(2 pending)+50.00%+118.01%+23.93%+94.09%+94.75%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
ADPT · 406,775 shares · as of Jun 25, 2026
0117,278234,557351,835469,113202120222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 12 buys / 12 sellsCOVERAGE · 24 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
ADPT
ADAPTIVE BIOTECHNOLOGIES CORP
SALE10b5-1
10b5-1 plan
5,000$20.50$102.5K406,775Jun 25, 2026Jun 29, 2026View →
ADPT
ADAPTIVE BIOTECHNOLOGIES CORP
SALE10b5-1
10b5-1 plan
5,000$19.00$95.0K411,775Jun 11, 2026Jun 15, 2026View →
ADPT
ADAPTIVE BIOTECHNOLOGIES CORP
SALE10b5-1
10b5-1 plan
11,000$18.00$198.0K416,775Jun 4, 2026Jun 8, 2026View →
ADPT
ADAPTIVE BIOTECHNOLOGIES CORP
SALE
Chief Commercial Officer, MRD
41,338$13.17$544.4K427,775Mar 11, 2026Mar 13, 2026View →
ADPT
ADAPTIVE BIOTECHNOLOGIES CORP
PURCHASEGRANT
Stock grant
59,375406,613Mar 4, 2026Mar 6, 2026View →
ADPT
ADAPTIVE BIOTECHNOLOGIES CORP
PURCHASEGRANT
Stock grant
62,500469,113Mar 4, 2026Mar 6, 2026View →
ADPT
ADAPTIVE BIOTECHNOLOGIES CORP
SALE
Chief Commercial Officer, MRD
26,023$6.98$181.6K347,238Mar 5, 2025Mar 6, 2025View →
ADPT
ADAPTIVE BIOTECHNOLOGIES CORP
PURCHASEGRANT
Stock grant
119,971373,261Mar 4, 2025Mar 6, 2025View →
ADPT
ADAPTIVE BIOTECHNOLOGIES CORP
PURCHASEGRANT
Stock grant
180,029180,029Mar 4, 2025Mar 6, 2025View →
ADPT
ADAPTIVE BIOTECHNOLOGIES CORP
SALE
Chief Commercial Officer, MRD
5,0000Oct 8, 2024Oct 10, 2024View →
ADPT
ADAPTIVE BIOTECHNOLOGIES CORP
PURCHASE
Chief Commercial Officer, MRD
5,000$1.98$9.9K253,290Oct 8, 2024Oct 10, 2024View →
ADPT
ADAPTIVE BIOTECHNOLOGIES CORP
SALE
Chief Commercial Officer, MRD
6,016$3.43$20.6K255,265Mar 5, 2024Mar 6, 2024View →
ADPT
ADAPTIVE BIOTECHNOLOGIES CORP
SALE
Chief Commercial Officer, MRD
6,975$3.44$24.0K248,290Mar 5, 2024Mar 6, 2024View →
ADPT
ADAPTIVE BIOTECHNOLOGIES CORP
PURCHASEGRANT
Stock grant
132,979261,281Mar 4, 2024Mar 6, 2024View →
ADPT
ADAPTIVE BIOTECHNOLOGIES CORP
PURCHASEGRANT
Stock grant
199,549199,549Mar 4, 2024Mar 6, 2024View →
ADPT
ADAPTIVE BIOTECHNOLOGIES CORP
PURCHASEGRANT
Stock grant
9,1589,158Mar 4, 2021Mar 8, 2021View →
ADPT
ADAPTIVE BIOTECHNOLOGIES CORP
PURCHASEGRANT
Stock grant
22,89422,894Mar 4, 2021Mar 8, 2021View →
ADPT
ADAPTIVE BIOTECHNOLOGIES CORP
PURCHASE
SVP, Diagnostics, clonoSEQ
25,000$1.98$49.5K25,000Dec 10, 2020Dec 11, 2020View →
ADPT
ADAPTIVE BIOTECHNOLOGIES CORP
SALE
SVP, Diagnostics, clonoSEQ
25,000$55.00$1.38M0Dec 10, 2020Dec 11, 2020View →
ADPT
ADAPTIVE BIOTECHNOLOGIES CORP
SALE
SVP, Diagnostics, clonoSEQ
25,00030,000Dec 10, 2020Dec 11, 2020View →
ADPT
ADAPTIVE BIOTECHNOLOGIES CORP
PURCHASE
SVP, Diagnostics, clonoSEQ
10,000$1.98$19.8K10,000Sep 29, 2020Oct 1, 2020View →
ADPT
ADAPTIVE BIOTECHNOLOGIES CORP
SALE
SVP, Diagnostics, clonoSEQ
10,00055,000Sep 29, 2020Oct 1, 2020View →
ADPT
ADAPTIVE BIOTECHNOLOGIES CORP
SALE
SVP, Diagnostics, clonoSEQ
10,000$50.00$500.0K0Sep 29, 2020Oct 1, 2020View →
ADPT
ADAPTIVE BIOTECHNOLOGIES CORP
PURCHASEGRANT
Stock grant
20,00020,000Aug 13, 2020Aug 14, 2020View →
Other insiders · ADPT
Loading peer insiders…
About this filer
CIK 0001820885
ROLE
Chief Commercial Officer, MRD
PRIMARY
ADPT
COMPANIES
1
ACTIVE SINCE
Aug 2020
MARKETPEEL · /INSIDER/0001820885DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback